‌

US Patent 11661459 Artificial cell death polypeptide for chimeric antigen receptor and uses thereof

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Century Therapeutics

0

Current Assignee

Century Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

May 30, 2023

0

Patent Application Number

174571420

Date Filed

December 1, 2021

0

Patent Citations

US Patent 8318491 Method of differentiating hematopoietic stem cells into natural killer cells using YC-1 or IL-21

0

US Patent 8338172 Methods for obtaining immortalized antibody secreting cells

0

US Patent 8389282 Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes

0

US Patent 8530636 Method for regulating protein function in cells in vivo using synthetic small molecules

0

US Patent 8546140 Methods for the production of iPS cells using non-viral approach

0

US Patent 8846395 Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin

0

US Patent 8906682 Methods for treatment of cancer

0

US Patent 8911993 Compositions for treatment of cancer

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

Provided are polynucleotides encoding inactivated cell surface receptors. Also provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11661459 Artificial cell death polypeptide for chimeric antigen receptor and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.